Oryzon Genomics S.A.
ORYZF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $254 | $212 | $185 | $100 |
| - Cash | $0 | $31 | $0 | $6 |
| + Debt | $0 | $14 | $0 | $11 |
| Enterprise Value | $254 | $195 | $185 | $106 |
| Revenue | $0 | $4 | $0 | $7 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | $0 | $4 | $0 | $7 |
| % Margin | – | 96.5% | – | 95.9% |
| EBITDA | -$5 | $0 | -$3 | $5 |
| % Margin | – | 7% | – | 72.2% |
| Net Income | $0 | -$0 | -$2 | -$1 |
| % Margin | – | -0.7% | – | -16.4% |
| EPS Diluted | 0.01 | -0 | -0.026 | -0.018 |
| % Growth | 2,600% | 98.5% | -49.7% | – |
| Operating Cash Flow | – | $0 | $0 | $0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | $0 | $0 | $0 |